Completed
Dose-Escalation Study of GSK2126458
NCT00972686
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
- Locations
-
- GSK Investigational Site San Francisco, California, United States
- GSK Investigational Site New Brunswick, New Jersey, United States
- GSK Investigational Site Chapel Hill, North Carolina, United States
- GSK Investigational Site Dallas, Texas, United States